Alumis (NASDAQ:ALMS) Reaches New 12-Month High After Insider Buying Activity

Alumis Inc. (NASDAQ:ALMS) hit a new 52-week high on Tuesday following insider buying activity. The company traded as high as $22.39 and last traded at $21.98, with a volume of 1607602 shares changing hands. The stock had previously closed at $21.09.

Specifically, major shareholder Foresite Labs, Llc bought 411,764 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The stock was bought at an average cost of $17.00 per share, with a total value of $6,999,988.00. Following the completion of the purchase, the insider owned 5,702,536 shares of the company’s stock, valued at approximately $96,943,112. The trade was a 7.78% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director James B. Tananbaum purchased 411,764 shares of the firm’s stock in a transaction on Thursday, January 8th. The stock was bought at an average price of $17.00 per share, for a total transaction of $6,999,988.00. Following the purchase, the director owned 5,702,536 shares in the company, valued at approximately $96,943,112. This represents a 7.78% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In other news, major shareholder Foresite Capital Management Vi acquired 411,764 shares of the business’s stock in a transaction dated Thursday, January 8th. The stock was purchased at an average price of $17.00 per share, for a total transaction of $6,999,988.00. Following the completion of the transaction, the insider directly owned 5,702,536 shares in the company, valued at approximately $96,943,112. This trade represents a 7.78% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Analyst Ratings Changes

ALMS has been the subject of a number of research reports. UBS Group reissued an “outperform” rating on shares of Alumis in a research note on Tuesday, January 6th. Guggenheim upped their price objective on Alumis from $18.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Leerink Partners raised their target price on shares of Alumis from $20.00 to $32.00 and gave the company an “outperform” rating in a report on Tuesday, January 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alumis in a research note on Monday, December 29th. Finally, Oppenheimer reissued an “outperform” rating and issued a $50.00 price objective on shares of Alumis in a research note on Tuesday, January 6th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $37.67.

Alumis News Summary

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Major insider/affiliated fund bought 411,764 shares (~$7.0M) at $17.00 per share, increasing their stake by ~7.8% to 5,702,536 shares — a direct vote of confidence from Director James B. Tananbaum / Foresite-affiliated entities. Filing: SEC Filing
• Positive Sentiment: Multiple news outlets reported the purchase, amplifying market attention and likely contributing to today’s volume spike and upward price pressure. (Example coverage) Investing.com article
• Positive Sentiment: Recent analyst activity: several firms (UBS, Oppenheimer, Guggenheim, Wells Fargo, Citi) have issued Outperform/Buy or raised price targets in early January, lifting consensus sentiment and supporting higher valuations. (Market commentary) MarketBeat coverage
• Neutral Sentiment: Short interest data in the alert is effectively zero/flat and shows no immediate squeeze signal; days-to-cover reported as 0.0, so short activity is not currently driving price action.
• Neutral Sentiment: Institutional holders (Vanguard, Samsara, Orbimed, Trium) have recently adjusted stakes — shows growing institutional interest but also concentration among a few large holders. Institutional holdings
• Negative Sentiment: Fundamental risk remains: Alumis missed Q3 EPS and revenue estimates in its last report (Nov. 13), underscoring execution and near-term cash/revenue risk despite optimism on pipeline. Earnings detail

Alumis Price Performance

The firm has a market cap of $2.31 billion, a P/E ratio of -5.46 and a beta of -2.09. The stock’s 50-day simple moving average is $9.54 and its two-hundred day simple moving average is $6.08.

Alumis (NASDAQ:ALMS) last released its quarterly earnings results on Thursday, November 13th. The company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.14). The company had revenue of $2.07 million for the quarter, compared to analysts’ expectations of $3.14 million. As a group, sell-side analysts expect that Alumis Inc. will post -8.51 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Samsara Biocapital LLC raised its holdings in shares of Alumis by 47.0% in the second quarter. Samsara Biocapital LLC now owns 4,801,370 shares of the company’s stock worth $14,404,000 after buying an additional 1,534,872 shares during the period. Foresite Capital Management VI LLC lifted its position in shares of Alumis by 1.1% in the 2nd quarter. Foresite Capital Management VI LLC now owns 4,247,670 shares of the company’s stock worth $12,743,000 after purchasing an additional 45,000 shares during the period. Vanguard Group Inc. boosted its stake in shares of Alumis by 18.4% during the third quarter. Vanguard Group Inc. now owns 4,029,615 shares of the company’s stock valued at $16,078,000 after purchasing an additional 625,404 shares in the last quarter. Trium Capital LLP increased its holdings in Alumis by 17.9% during the third quarter. Trium Capital LLP now owns 3,122,111 shares of the company’s stock valued at $12,457,000 after buying an additional 474,072 shares during the period. Finally, Orbimed Advisors LLC purchased a new stake in Alumis during the second quarter worth $5,779,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.